MET-2
/ NuBiyota
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
July 05, 2023
A microbial consortium alters intestinal Pseudomonadota and antimicrobial resistance genes in individuals with recurrent Clostridioides difficile infection.
(PubMed, mBio)
- "We evaluated whether a microbial consortium had similar effects to FMT on Pseudomonadota abundances and ARGs as well as obligate anaerobes and beneficial butyrate producers in individuals with high Pseudomonadota relative abundance at baseline. This study provides support for a randomized, controlled clinical trial of microbial consortia (such as MET-2) for ARO decolonization and anaerobe repletion."
Clinical • Journal • Infectious Disease • Transplantation
May 03, 2021
Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC)
(clinicaltrials.gov)
- P1b; N=11; Completed; Sponsor: NuBiyota; Active, not recruiting ➔ Completed; N=30 ➔ 11
Clinical • Enrollment change • Trial completion • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
May 04, 2021
The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression
(clinicaltrials.gov)
- P2; N=60; Recruiting; Sponsor: NuBiyota; Not yet recruiting ➔ Recruiting; Initiation date: Dec 2020 ➔ Apr 2021
Clinical • Enrollment open • Trial initiation date • CNS Disorders • Depression • Major Depressive Disorder • Mood Disorders • Psychiatry
October 26, 2020
The Safety, Efficacy, and Tolerability of Microbial Ecosystem Therapeutic-2 in People With Major Depression
(clinicaltrials.gov)
- P2; N=60; Not yet recruiting; Sponsor: NuBiyota
Clinical • New P2 trial • CNS Disorders • Depression • Mood Disorders • Psychiatry
1 to 4
Of
4
Go to page
1